Benitec BioPharma (BNTC) Reiterated at Market Outperform by Citizens on Q3 Update

May 18, 2026 7:20 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $24.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found